ES2055761T3 - Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x. - Google Patents

Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.

Info

Publication number
ES2055761T3
ES2055761T3 ES89112443T ES89112443T ES2055761T3 ES 2055761 T3 ES2055761 T3 ES 2055761T3 ES 89112443 T ES89112443 T ES 89112443T ES 89112443 T ES89112443 T ES 89112443T ES 2055761 T3 ES2055761 T3 ES 2055761T3
Authority
ES
Spain
Prior art keywords
factors
procedure
vii
concentration
blood coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89112443T
Other languages
English (en)
Spanish (es)
Inventor
Michael Dipl-Bio Kraus
Wolfgang Dr Dipl-Chem Moller
Bertram Dr Eichentopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EICHENTOPF BERTRAM PHARMA
Original Assignee
EICHENTOPF BERTRAM PHARMA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EICHENTOPF BERTRAM PHARMA filed Critical EICHENTOPF BERTRAM PHARMA
Application granted granted Critical
Publication of ES2055761T3 publication Critical patent/ES2055761T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES89112443T 1988-08-06 1989-07-07 Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x. Expired - Lifetime ES2055761T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3826792A DE3826792C1 (enExample) 1988-08-06 1988-08-06

Publications (1)

Publication Number Publication Date
ES2055761T3 true ES2055761T3 (es) 1994-09-01

Family

ID=6360383

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89112443T Expired - Lifetime ES2055761T3 (es) 1988-08-06 1989-07-07 Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.

Country Status (6)

Country Link
US (1) US5071961A (enExample)
EP (1) EP0354354B1 (enExample)
JP (1) JP2579217B2 (enExample)
AT (1) ATE104987T1 (enExample)
DE (2) DE3826792C1 (enExample)
ES (1) ES2055761T3 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914869C1 (enExample) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
JP3055933B2 (ja) * 1989-07-20 2000-06-26 アナリティカル・コントロール・システムズ・インコーポレーテッド 改良された安定な凝固対照
JP3418621B2 (ja) * 1991-03-01 2003-06-23 アヴェンティス ベーリング エルエルシー Ｉｘ因子の調製
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
DE19504852C2 (de) * 1995-02-15 2003-01-23 Octapharma Ag Lachen Verfahren zur Reinigung Vitamin K-abhängiger Gerinnungsfaktoren durch Affinitäts-Chromatographie
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
JP3023657B2 (ja) * 1995-09-25 2000-03-21 本田技研工業株式会社 自動２輪車のリヤスイングアーム
US5762757A (en) * 1996-12-05 1998-06-09 Betzdearborn Inc. Methods for inhibiting organic contaminant deposition in pulp and papermaking systems
FR2948665B1 (fr) 2009-07-31 2011-09-23 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla actives
FR2948664B1 (fr) 2009-07-31 2013-11-01 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla
JP2012050386A (ja) * 2010-09-01 2012-03-15 Kaneka Corp ２種類以上の多孔質充填剤を充填するカラム
JP5836577B2 (ja) * 2010-09-14 2015-12-24 株式会社カネカ クリングル配列を有する蛋白質またはペプチドを精製または除去するアフィニティ担体の製造方法、その精製方法、除去方法
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE15489T1 (de) * 1980-05-27 1985-09-15 Miles Lab Die blutkoagulation aktivierendes produkt und verfahren zu dessen herstellung.
DE3033932C2 (de) * 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
NL8701915A (nl) * 1987-08-14 1989-03-01 Waander Riethorst Adsorbensmateriaal en toepassing daarvan voor het isoleren van stollingsfaktoren.
CA1330302C (en) * 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use

Also Published As

Publication number Publication date
EP0354354A2 (de) 1990-02-14
EP0354354B1 (de) 1994-04-27
DE58907555D1 (de) 1994-06-01
US5071961A (en) 1991-12-10
JP2579217B2 (ja) 1997-02-05
DE3826792C1 (enExample) 1989-07-06
JPH02113893A (ja) 1990-04-26
EP0354354A3 (en) 1990-08-16
ATE104987T1 (de) 1994-05-15

Similar Documents

Publication Publication Date Title
ES2055761T3 (es) Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.
DE69230670D1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
ES2074490T3 (es) Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
ES2119411T5 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
ATE50493T1 (de) Ibuprofen enthaltendes arzneimittel.
DE3577397D1 (de) Fluessige diclofenac-zubereitungen.
ATE183387T1 (de) Pharmazeutische und andere darreichungsformen
ATE101517T1 (de) Pharmazeutische zusammensetzung, enthaltend loratadin, ibuprofen und pseudoephedrin.
SE8803486D0 (sv) Dosage form for treating cardiovascular diseases
ES2052495T3 (es) Terapia de fluidos con aniones l-lactato y/o piruvato.
ES2055587T3 (es) El uso de agonistas selectivos de gaba-b como agentes antitusivos.
CA2098021A1 (en) Composition Used as a Therapeutic Agent Against Chronic Viral Hepatic Diseases
PT98193A (pt) Estojo para a dosagem especifica de angiotensina ii
DE59407457D1 (de) Blockierung der anlagerung von keimen an menschliche zellen
ATE138590T1 (de) Pyrogensorbentmittel
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
DK0626857T3 (da) Forbedrede peritoneale dialyseopløsninger med polypeptider
SE8400723D0 (sv) Farmaceutisk komposition
DK0426610T3 (da) Ikke-ionisk røntgenkontrastmiddel med højt jodindhold
UY24063A1 (es) Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos
ES2056149T3 (es) Ambliommina, una nueva sustancia activa para la terapia anticoagulante.
ES2054200T3 (es) Solucion de dialisis y lavado para la administracion por via intraperitoneal.
IT8748116A0 (it) Derivati di glicina in qualita' di agenti preventivi e terapeutici del le complicanze diabetiche